PRINCETON, N.J. and SUZHOU, China, April 26, 2024 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to present results of cohort G from a phase I/IIa study: first-line Osemitamab (TST001) plus Nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..

SUZHOU, China, October 19, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to present three posters highlighting study results from ongoing trials related to Osemitamab (TST001) at the 2023 European Society of Medical Oncology (ESMO) Congress including updated efficacy and PK/PD analysis data from the phase 2 study of Osemitamab (TST001)/CAPOX in CLDN18.2 positive first line G/GEJC as well as preclinical data on the combination study of Osemitamab (TST001) with PD1 inhibitor.

SUZHOU, China, June 16, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that efficacy data by CLDN18.2 expression level from phase 1/2 study of Osemitamab (TST001) plus Capecitabine and Oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer will be presented as a poster at 2023 ESMO World GI.